全文获取类型
收费全文 | 8802篇 |
免费 | 425篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 159篇 |
儿科学 | 121篇 |
妇产科学 | 105篇 |
基础医学 | 937篇 |
口腔科学 | 132篇 |
临床医学 | 614篇 |
内科学 | 2221篇 |
皮肤病学 | 246篇 |
神经病学 | 639篇 |
特种医学 | 397篇 |
外科学 | 1627篇 |
综合类 | 26篇 |
一般理论 | 1篇 |
预防医学 | 264篇 |
眼科学 | 153篇 |
药学 | 448篇 |
中国医学 | 16篇 |
肿瘤学 | 1184篇 |
出版年
2023年 | 79篇 |
2022年 | 47篇 |
2021年 | 261篇 |
2020年 | 139篇 |
2019年 | 189篇 |
2018年 | 226篇 |
2017年 | 150篇 |
2016年 | 198篇 |
2015年 | 215篇 |
2014年 | 289篇 |
2013年 | 298篇 |
2012年 | 503篇 |
2011年 | 609篇 |
2010年 | 344篇 |
2009年 | 272篇 |
2008年 | 490篇 |
2007年 | 578篇 |
2006年 | 591篇 |
2005年 | 642篇 |
2004年 | 626篇 |
2003年 | 560篇 |
2002年 | 518篇 |
2001年 | 143篇 |
2000年 | 141篇 |
1999年 | 145篇 |
1998年 | 98篇 |
1997年 | 71篇 |
1996年 | 81篇 |
1995年 | 71篇 |
1994年 | 57篇 |
1993年 | 57篇 |
1992年 | 62篇 |
1991年 | 67篇 |
1990年 | 37篇 |
1989年 | 62篇 |
1988年 | 40篇 |
1987年 | 45篇 |
1986年 | 44篇 |
1985年 | 27篇 |
1984年 | 22篇 |
1983年 | 23篇 |
1982年 | 16篇 |
1981年 | 13篇 |
1980年 | 18篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1975年 | 12篇 |
1974年 | 13篇 |
1969年 | 11篇 |
1968年 | 10篇 |
排序方式: 共有9290条查询结果,搜索用时 31 毫秒
1.
Takafumi Koyama Toshio Shimizu Satoru Iwasa Yutaka Fujiwara Shunsuke Kondo Shigehisa Kitano Kan Yonemori Akihiko Shimomura Sakura Iizumi Tatsuya Sasaki Junji Furuse Noboru Yamamoto 《Cancer science》2020,111(2):571-579
Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1‐3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1‐180 mg) was carried out to assess dose‐limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25‐(OH)2‐vitamin D) were also evaluated. A total of 24 patients refractory to standard therapy or for whom no appropriate treatment was available were enrolled. No DLT were observed up to the 140‐mg dose; one patient in the 180‐mg cohort experienced a DLT (increased aspartate aminotransferase/alanine aminotransferase, grade 3). The maximum tolerated dose was not reached. Dose‐dependent increases in the maximum concentration and area under the curve from time 0 to the last measurable concentration were observed up to 180 mg. Dose‐dependent increases were observed in all pharmacodynamic markers and plateaued at 100‐140 mg, indicating sufficient FGFR pathway inhibition at doses ≥100 mg. In conclusion, E7090 showed a manageable safety profile with no DLT at doses ≤140 mg. Maximum tolerated dose was not determined. The recommended dose for the follow‐up expansion part, restricted to patients with tumors harboring FGFR alterations, was determined as 140 mg, once daily. 相似文献
2.
Mamiko Onuki Koji Matsumoto Takashi Iwata Kasumi Yamamoto Yoichi Aoki Shoji Maenohara Naotake Tsuda Shoji Kamiura Kazuhiro Takehara Koji Horie Nobutaka Tasaka Hideaki Yahata Yuji Takei Yoichi Aoki Hisamori Kato Takeshi Motohara Keiichiro Nakamura Mitsuya Ishikawa Tatsuya Kato Hiroyuki Yoshida Noriomi Matsumura Hidekatsu Nakai Shogo Shigeta Fumiaki Takahashi Kiichiro Noda Nobuo Yaegashi Hiroyuki Yoshikawa 《Cancer science》2020,111(7):2546-2557
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2‐3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33), and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14‐0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95% CI, 88.7‐90.7) of CIN2‐3/AIS and 93.8% (95% CI, 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women. 相似文献
3.
Andrew X. Zhu Richard S. Finn Yoon-Koo Kang Chia-Jui Yen Peter R. Galle Josep M. Llovet Eric Assenat Giovanni Brandi Kenta Motomura Izumi Ohno Bruno Daniele Arndt Vogel Tatsuya Yamashita Chih-Hung Hsu Guido Gerken John Bilbruck Yanzhi Hsu Kun Liang Ryan C. Widau Chunxiao Wang Paolo Abada Masatoshi Kudo 《British journal of cancer》2021,124(8):1388
Background Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or progression, during treatment in two placebo-controlled trials (REACH, REACH-2).Methods Serum AFP was measured at baseline and every three cycles. The prognostic and predictive value of baseline AFP was assessed by Cox regression models and Subpopulation Treatment Effect Pattern Plot method. Associations between AFP (≥ 20% increase) and radiographic progression and efficacy were assessed.Results Baseline AFP was confirmed as a continuous (REACH, REACH-2; p < 0.0001) and dichotomous (≥400 vs. <400 ng/ml; REACH, p < 0.01) prognostic factor, and was predictive for ramucirumab survival benefit in REACH (p = 0.0042 continuous; p < 0.0001 dichotomous). Time to AFP (hazard ratio [HR] 0.513; p < 0.0001) and radiographic (HR 0.549; p < 0.0001) progression favoured ramucirumab. Association between AFP and radiographic progression was shown for up to 6 (odds ratio [OR] 5.1; p < 0.0001) and 6–12 weeks (OR 1.8; p = 0.0065). AFP response was higher with ramucirumab vs. placebo (p < 0.0001). Survival was longer in patients with an AFP response than patients without (13.6 vs. 5.6 months, HR 0.451; 95% confidence interval, 0.354–0.574; p < 0.0001).Conclusions AFP is an important prognostic factor and a predictive biomarker for ramucirumab survival benefit. AFP ≥ 400 ng/ml is an appropriate selection criterion for ramucirumab.Clinical Trial Registration ClinicalTrials.gov, REACH () and REACH-2 ( NCT01140347).Subject terms: NCT02435433Oncology, Biomarkers 相似文献
4.
Yushi Katsuyama Norihisa Taira Tatsuya Tsuboi Masato Yoshioka Yuri Okano Hitoshi Masaki 《Experimental dermatology》2019,28(Z1):64-68
Skin sensitivity is a serious problem for many people, and it can be induced by various factors such as UV irradiation, physical and mental stresses, air pollution, dry air and so on. Skin dryness triggered by UV and dry air is one of the most important causes inducing the development of sensitive skin, and it has been reported that oxidative stress contributes to skin dryness. In this study, we investigated whether treatment with 3‐O‐laurylglyceryl ascorbate (VC‐3LG), which is an amphipathic ascorbic acid derivative, can suppress the development of sensitive skin. The results demonstrate that VC‐3LG restores the expression levels of interleukin‐1α, nerve growth factor and matrix metalloprotease‐9 in the dry skin models of reconstructed human epidermal equivalents (RHEEs) and in H2O2‐treated keratinocytes. In addition, VC‐3LG suppresses the dendrite elongation of nerve cells induced in RHEEs by dry skin conditions and by H2O2 treatment of keratinocytes. Therefore, we consider that treatment of the skin with VC‐3LG is an effective approach to improve the development of sensitive skin. 相似文献
5.
6.
7.
Tetsuya Katsumori Tatsuya Yoshikawa Yasuteru Sasakura Toshinori Yasumura Mitsuhiro Hisano 《Journal of vascular and interventional radiology : JVIR》2021,32(3):332-338
PurposeTo investigate differences in outcomes of uterine artery embolization (UAE) for leiomyoma when performed during different phases of the menstrual cycle.Materials and MethodsIn this single-institution retrospective analysis, 111 premenopausal patients (median [range] age, 44 [33–52] years) undergoing UAE for symptomatic leiomyoma between June 2014 and February 2020 were included. Twenty-one patients underwent UAE in the menstrual phase (the early follicular phase), 27 in the late follicular phase, and 63 in the luteal phase. Baseline characteristics and technical and peri-procedural outcomes were compared among groups. Leiomyoma infarction on contrast-enhanced magnetic resonance imaging 1 week after UAE and 4-month outcomes, including changes in the Uterine Fibroid Symptom and Quality of Life questionnaire scores, the volume reduction rates of the uterus and largest leiomyoma, follicle stimulating hormone values, adverse events, and amenorrhea, were compared among groups.ResultsA 4-month follow-up was completed for all patients. No significant differences were observed among groups in baseline characteristics or technical and peri-procedural outcomes. There were no significant differences in the multivariate-adjusted 1-week infarction rates of all leiomyoma volumes (P = .161) or multivariate-adjusted 4-month outcomes, including changes in the Uterine Fibroid Symptom and Quality of Life questionnaire symptoms and total scores (P = .864 and P = .798, respectively), the volume reduction rates of the uterus and the largest leiomyoma (P = .865 and P = .965, respectively), and follicle stimulating hormone values (P = .186) among the groups. No significant differences were noted in the 4-month adverse events (P = .260) or amenorrhea (P = .793) among the groups.ConclusionsThe present study demonstrated no significant differences in the outcomes of UAE for leiomyoma when performed during different phases of the menstrual cycle. 相似文献
8.
Yuki Matsumoto Mikiko Kobayashi Kunihiko Shingu Ayako Tateishi Maki Ohya Kenji Sano Tatsuya Negishi Shohei Shigeto Tatsuya Kobayashi Yosuke Hara Yukinari Kakizawa Hiroyuki Kanno 《Neuropathology》2020,40(5):507-514
Pleomorphic xanthoastrocytomas (PXAs) are rare low-grade astrocytic tumors that typically present as superficial nodular cystic tumors of the cerebrum attached to the leptomeninx. Histologically, they are pleomorphic, hypercellular glial neoplasms. Despite the presence of microscopic pleomorphism, patients’ postoperative prognosis is generally good. Anaplastic PXAs (APXAs) have a high mitotic index and patients with APXAs have a worse prognosis than patients with PXAs. Here, we report an autopsy case of APXA initially diagnosed as PXA. After gross total resection, the tumor recurred and was diagnosed as an APXA; thereafter, the patient died. An autopsy revealed that the tumor had relapsed at the primary site and had spread to the leptomeningeal space while concurrently invading the cerebrum including the periventricular area forming multifocal lesions. The histological findings of the autopsy were similar to those for epithelioid glioblastoma (EGBM) and small cell glioblastoma (SCGBM). In particular, the periventricular area with multifocal lesions was composed of SCGBM-like cells. It has been shown that multifocal lesions are frequently identified in patients with SCGBM. This is the first histopathologically confirmed case of APXA-related tumor presenting with periventricular extension and multifocal lesion formation. The periventricular extension might be a feature of PXAs and APXAs. However, suspected periventricular spread on imaging in past cases of PXAs and APXAs might instead represent the malignant transformation of these tumors to glioblastoma-like high-grade tumors, which often show SCGBM-like histological patterns. 相似文献
9.
10.
Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute 下载免费PDF全文
Masaki Otsuka Osamu Yamasaki Tatsuya Kaji Keiji Iwatsuki Kenji Asagoe 《The Journal of dermatology》2015,42(10):954-961
Sentinel lymph node biopsy (SLNB) is a widely accepted standard procedure for patients with clinically localized melanoma. Melanoma prevalence and Clark's subtype differ between Asians and Caucasians. Here, we evaluated our experience on SLNB for cutaneous melanoma in a Japanese population. SLNB was performed for patients with melanoma between July 2000 and June 2014. We retrospectively analyzed 102 patients regarding association of clinicopathological features with sentinel lymph node (SLN) status, melanoma‐specific survival (MSS) and disease‐free survival (DFS). A positive SLN was significantly associated with primary Breslow thickness. Compared with 43 patients with negative SLN, 59 patients with positive SLN had significantly shorter MSS (5‐year survival rate, 94.3% vs 63.2%; P = 0.0002) and DFS (5‐year survival rate, 92.7% vs 63.4%; P = 0.0004). According to our subgroup analyses, nine patients with positive non‐SLN had significantly shorter MSS compared with 32 patients with negative non‐SLN (5‐year survival rate, 32.4% vs 68.5%; P = 0.0273). The survival of 51 Japanese patients with acral lentiginous melanoma (ALM) was not inferior to the survival of patients with other Clark's subtype. Breslow thickness is an important factor for both MSS and DFS, and the status of SLN is the most predictive prognostic factor in Japanese patients with clinically localized melanomas, as in case of Caucasians. Features of ALM may be different between Asians and Caucasians. 相似文献